Press Releases
August 17, 2026
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
August 10, 2026
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
July 31, 2026
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
July 31, 2026
Lupin Announces the Approval of Diazepam Injection, USP in the United States
July 21, 2026
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
July 1, 2026
Lupin Announces EMA Approval for NaMuscla® Expansion for Pediatric Indication with New Strengths
June 26, 2026
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
June 17, 2026
Lupin Launches Azilsartan Medoxomil Tablets in the United States
June 8, 2026
Lupin Collaborates with ERN for Luforbec®(beclometasone/formoterol) pMDI Launch in Spain
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
Search Product

Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.
